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Despite a wealth of activity across the globe in the area of longitudinal population
cohorts, surprisingly little information is available on the natural biomedical history
of a number of age-related neurodegenerative diseases (ND), and the scope for
intervention studies based on these cohorts is only just beginning to be explored. The
Joint Programming Initiative on Neurodegenerative Disease Research (JPND) recently
developed a novel funding mechanism to rapidly mobilize scientists to address these
issues from a broad, international community perspective. Ten expert Working Groups,
bringing together a diverse range of community members and covering a wide ND
landscape [Alzheimer’s, Parkinson’s, frontotemporal degeneration, amyotrophic lateral
sclerosis (ALS), Lewy-body and vascular dementia] were formed to discuss and propose
potential approaches to better exploiting and coordinating cohort studies. The purpose
of this work is to highlight the novel funding process along with a broad overview
of the guidelines and recommendations generated by the ten groups, which include
investigations into multiple methodologies such as cognition/functional assessment,
biomarkers and biobanking, imaging, health and social outcomes, and pre-symptomatic
ND. All of these were published in reports that are now publicly available online.
Keywords: longitudinal cohort studies, research, transnational working groups, flexible funding mechanism, joint
programming, neurodegenerative disease
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INTRODUCTION
Neurodegenerative diseases (ND) are debilitating conditions
that affect neurons, primarily in the human brain and, in
some cases, the spinal cord. Neurons are typically unable
to reproduce or repair themselves, so when they become
damaged or die they cannot be replaced by the body. There
are currently no treatments for ND, which result in the
progressive degeneration and/or death of nerve cells. This
causes problems with movement (called hypo-/bradykinesia,
tremor or ataxias), muscle strength (called motor neuron
diseases) or mental functioning (called dementias). Dementias
are responsible for one of the greatest challenges facing the
world’s health and social care systems, with Alzheimer’s disease
(AD) representing approximately 60–70% of all dementia
cases.
The Joint Programming Initiative on Neurodegenerative
Disease Research (JPND) brings together 30 countries to
accelerate research progress in the ND field by defragmenting
and aligning national investments and research agendas. Since
its first call for proposals in 2011, JPND has raised more
than €100 million of new money from national budgets of
participating counties and has supported more than 70 trans-
national research projects from EU member (and associated)
states and partner countries such as Canada, Switzerland and
Australia.
In 2014, JPND created a novel funding mechanism to support
ten new, international expertWorkingGroups focused on rapidly
building consensus around some of the major challenges facing
the use of cohorts for ND research. The purpose of this paper is
to present this funding process along with a broad overview of the
guidelines and recommendations generated by the ten groups, all
of which are now publicly available in their full version online.
Each Working Group addressed different issues that contribute
to cohorts being under-used for ND research. We hope that
readers considering the use of cohort studies for ND research will
be interested to find outmore by going to the relevant reports and
full publications.
Longitudinal Cohort Studies in ND
Research
Longitudinal cohort studies, which gather data on populations
over time in order to establish correlations, are widely
acknowledged as important resources for multi-disciplinary
ND research into the causes and progression of disease
(e.g., determining risk factors). Linking and comparing such
studies together would allow researchers to draw broader and
statistically more powerful conclusions that could lead to a far
deeper understanding of disease. Yet significant methodological
variations across cohort studies, including in data collection,
measurement, and analysis, impede such linkages. In short,
cohort studies are not yet able to be fully leveraged for the
needs of ND research, with the potential for more to be done to
promote (i) untapped research opportunities they might provide,
(ii) best practices in data collection/analysis, and (iii) accessibility
of study data.
In 2013, JPND published a report1 identifying gaps and
cases for new activity in areas of unmet need and outlining
how to add value to existing cohort investments. The report
demonstrated that despite a wealth of cohort activity across
Europe, surprisingly little information is available on the natural
biomedical history of ND, and the scope for intervention studies
based on these cohorts is only just beginning to be explored.
Given the opportunities offered by the recent evidence for
convergence amongst risk factors and underlying pathologies
across ND, it appears essential that steps are taken to improve
and coordinate existing capabilities. Examples include the links
between immune system disruption and AD, protein aggregation
underlying AD, PD and prion disease, the commonality in
C9orf72 hexanucleotide repeat expansions between forms of
frontotemporal degeneration (FTD) and amyotrophic lateral
sclerosis (ALS) and the high prevalence of vascular disease that
includes risk factors and clinical expression of AD (Goedert,
2015; Rohrer et al., 2015; Colonna and Wang, 2016).
A Novel, Flexible Funding Mechanism to
Accelerate Progress
Based on the recommendations from the 2013 report, JPND
began developing actions to produce the methodological and
technical solutions required to catalyze progress in this area,
both to promote better use of existing data across studies, and to
provide a more interoperable approach to future data collection.
Specifically, JPND devised a new funding process called a
“rapid action” call to bring together key leaders in the field to
discuss and propose potential solutions to the barriers holding up
progress. This call, launched in April 2014, established Working
Groups, made up of a diverse range of community members,
to collaborate across national and disciplinary borders with
the ultimate aim of producing methodologies and frameworks
that could help the international scientific community optimize
the use of cohort studies for ND research. This could be
done either by providing a framework for exploiting and
harmonizing existing or planned cohort studies and/or as a basis
for developing new research proposals.
Working Groups were identified by JPND on a competitive
basis, with each group receiving up to €50 k to enable it to
deliver its work within 6 months. Twenty-two applications were
received, of which ten were recommended for funding by the
review panel; the successful applications, comprising some 200
researchers, represent a diverse range of ND and methodologies,
as summarized in Table 1. Indeed, members of the Working
Groups go beyond the 30 JPND member countries and include
experts based in several additional countries, including China,
Russia, Singapore and the USA.
Working Groups typically brought together 10–20 leading
experts to address a specific topic area, and were asked to hold
two workshops over a 6-month period, communicating by tele-
or video conference in the time betweenmeetings (Figure 1). The
incorporation of external reference groups was encouraged, to
1http://www.neurodegenerationresearch.eu/uploads/media/JPNDAGLCS_Final_
Report_Oct_2013-version_07_01_14.pdf
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TABLE 1 | List of ten funded Working Groups.
Working group Coordinator and sponsor country Number of
countries
HD-READy (High-Dimensional Research in Alzheimer’s Disease) M. Arfan Ikram, Erasmus University Medical Centre, Rotterdam, Netherlands
Sponsor country: Netherlands
Eight
Harmonization and innovation of cognitive, behavioral and functional
assessment in neurodegenerative dementias
Alberto Costa, IRCCS Fondazione Santa Lucia, Rome, Italy
Sponsor country: Italy
Nine
NETCALS (Network of Cohort Assessment in ALS) Leonard van den Berg, University Medical Centre Utrecht, Utrecht, Netherlands
Sponsor country: France
Twelve
21st Century Eurodem—Repurposing Cohorts for Dementia Studies Carol Brayne, University of Cambridge, UK
Sponsor country: Sweden
Ten
Multi-center cohort-studies in Lewy-body dementia: Challenges in
harmonizing different clinical and biomarker protocols
Dag Aarsland, Stavanger University Hospital, Stavanger, Norway
Sponsor country: Norway
Nine
Presymptomatic Neurodegeneration Initiative (PreNI): Developing a
methodological framework for trials in presymptomatic
neurodegenerative disease
Jonathan Rohrer, University College London, UK
Sponsor country: UK
Six
Harmonization of biomarker assessment in longitudinal cohort studies
in Parkinson’s disease
Daniela Berg, Hertie-Institute for Clinical Brain Research and German Center for
Neurodegenerative Diseases, Tübingen, Germany
Sponsor country: Germany
Seven
Dementia Outcome Measures: Charting New Territory Gail Mountain, University of Sheffield, UK
Sponsor country: Denmark
Five
Body fluid biobanking of longitudinal cohorts in neurodegenerative
diseases
Charlotte Teunissen, VU University Medical Centre, Amsterdam, Netherlands
Sponsor country: Luxembourg
Five
METACOHORTS: Realizing the potential of cohort studies to determine
the vascular contribution to neurodegeneration
Joanna Wardlaw, University of Edinburgh, Edinburgh, UK
Sponsor country: Canada
Eleven
ensure both objectivity of outputs and that they would be of the
most use to the wider research community.
The first awards weremade in August 2014, just 4months after
the launch of the call, with the final reports for the ten Working
Groups received by June 2015, followed by their publication on
the JPND website in October 20152.
RESULTS
The ten Working Groups assembled under this funding action
produced wide-ranging work across a broad spectrum of
ND research. Some examples of their accomplishments are
highlighted below.
Realizing the Potential of Cohort Studies to
Determine Vascular Contributions to
Neurodegeneration
It is estimated that a third of all dementias are due wholly or
in part to vascular disease. Although vascular risk is modifiable,
little is currently understood about the vascular contribution
to neurodegeneration or how to treat it. The objective of the
METACOHORTS Working Group was to elucidate how cohort
studies might be better leveraged to investigate these links.
Led by Joanna Wardlaw from the University of Edinburgh,
METACOHORTS brought together 55 international experts on
2http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-actions/
longitudinal-cohorts/call-for-working-groups/reports
brain disease and dementia to survey data from more than
90 studies, representing more than 660,000 participants. The
researchers uncovered a tremendous amount of new information
from existing studies that had little overlap with any previous
data collections, suggesting that the value of mining such data
can be very high (Dichgans et al., 2016). This Working Group
subsequently secured EU Horizon 2020 funding to examine
mechanisms of microvascular disease as a common cause of
stroke and dementia, based on multi-center studies. Future
impact of the work is expected to include the integration of
stroke and dementia prevention clinics; research in AD that
better assesses vascular risk factors; and research in stroke that
routinely assesses cognition as well as physical outcomes.
Dementia Outcome Measures: Charting
New Psychosocial Territory
In this Working Group, Gail Mountain of the University
of Sheffield coordinated a group of experts focused on
identifying the best outcome measures for the assessment
of psychosocial interventions in dementia research. Starting
from the premise that enabling people to live well with a
dementia diagnosis is a key research objective, the group
aimed both to develop recommendations regarding the use of
existing outcome measures and to investigate the need for new
measures.
When surveying the existing measures commonly used
for people with dementia and their supporters, the group
identified several challenges. For example, they noted that “no
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FIGURE 1 | This diagram illustrates the Working Group approach to delivery through workshops, other communications and a final report.
single theory currently provides an adequate basis for defining
wellbeing in dementia,” with much of the literature rooted in
a “medical loss/deficit paradigm of dementia care”3. Moreover,
they found that the majority of existing measures do not enable
people with dementia to report data on their own behalf,
which can be problematic in light of research showing that
proxy ratings (usually from careers) often conflict with those
offered by the people living with dementia themselves4. The
group shortlisted 33 measures for psychosocial intervention
research, 16 of which were ultimately strongly recommended
to the research community. The group also made a series
of recommendations for novel measures. For example, the
group determined that new measures not predicated upon
recall should be developed. Further recommendations called
for the establishment of measures that could be self-completed
by people with early or moderate stages of dementia, and for
the use of special technology and visual methods for people
at more advanced stages. The outputs of this group, which
resulted from four face-to-face workshops, a year of desk-based
work, and a consultation with people living with dementia,
aim to better facilitate the collation of data from cohorts of
people with dementia who participate in psychosocial research
across different countries. This paves the way for data sharing,
3http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-
Report-Fountain.pdf
4Ibid.
ultimately helping to shape the remit and quality of future
psychosocial research across the dementia trajectory5.
High Dimensional Research in Alzheimer’s
Disease (HD-READy)
A cornerstone of ND research has always been the use of state-
of-the-art technologies and especially imaging and genetics.
Thus far, these two fields have mostly operated independently,
yet many methodological considerations overlap. Both are
high-throughput technologies requiring specific analytical
strategies. For instance, genome-wide association studies are
hypothesis-free screens of the entire genome for subtle signals
involved in ND; similarly, voxel-based approaches interrogate
the entire brain without assuming any pre-knowledge for
regions affected in ND. In the coming years, these two fields will
move closer together, opening up potentially novel avenues for
research, but also bringing a new set of challenges, which the
HD-READyWorking Group, coordinated by Arfan Ikram of the
Erasmus University Medical Centre, set out to address.
The starting point revolved around the question of how to
approach a voxel-based, genome-wide association study in terms
of the methodological, analytical, statistical, and computational
challenges to overcome and perform, for each single voxel in the
brain (n= 1,000,000), an entire genomic screen (n= 10,000,000).
Using simulation and real-world datasets, the group published
5Ibid.
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a set of recommendations and developed a novel analytical
strategy (Adams et al., 2016; Roshchupkin et al., 2016) that
can aid ND research aiming to combine imaging and genetics.
The recommendations are based on four HD-READy core
principles: setting (population-based vs. clinical), speed, sharing
and statistics. International consortia, such as CHARGE (Psaty
and Sitlani, 2013) and ENIGMA (Thompson et al., 2014), are
already incorporating these recommendations in their workflows
with respect to imaging and genetics. Importantly, this novel
methodology can also easily be applied to other hypothesis-free,
omics-technologies6.
Multi-Center Cohort Studies in Dementia
with Lewy Bodies: Harmonizing Clinical
and Biomarker Protocols
This Working Group, coordinated by Dag Aarsland of Stavanger
University Hospital, focused on the use of cohort studies in
research on dementia with Lewy bodies (DLB). Few longitudinal
studies currently exist and very little is known about the
prodromal phases of DLB—information that is crucial for both
clinical management and research. This group facilitated the
creation of a new European DLB consortium, which has rapidly
grown and collected retrospective data on >1,200 DLB patients.
Recommendations were made on how best to combine data from
different existing cohorts with different protocols and to pave
the way for future cohort studies7. The consortium also serves
as a trial-ready cohort and study leaders have been engaged in
discussions with companies aiming to carry out trials in DLB.
Finally, new funding is currently being sought for a prospective
study (Biundo et al., 2016).
Developing a Methodological Framework
for Trials in Pre-symptomatic ND
Multi-center pre-symptomatic trials aim to characterize an ND
from its earliest stages, establish disease biomarkers, and develop
cohorts large enough for clinical trials. Yet pre-symptomatic
trials for ND face a range of complex design and ethical
challenges. The Pre-symptomatic Neurodegeneration Initiative
(PreNI) Working Group, led by Jonathan Rohrer of the
University College London Dementia Research Centre, cataloged
these crucial challenges and drafted a set of guidelines for
improved planning of future trials.
The group issued a set of 14 recommendations covering
trial design, inclusion criteria, and the use of biomarkers. Since
measures such as time-to-symptoms can lead to lengthy clinical
trials, the group advocated for the need for shorter trials,
highlighting the need for “proximity markers,” i.e., markers that
identify a period in proximity to symptom onset. Furthermore,
the group supported the use of adaptive trial design in order
to increase efficiency and allow for the testing of more drugs
over a shorter period. With regard to inclusion criteria, the
group recommended selecting subjects for participation as early
as possible, before significant irreversible neuronal loss occurs,
6http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-
Report-Ikram.pdf
7http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-
Report-Aarsland.pdf
which would require the development of imaging and fluid
biomarkers for early-phase trials. The group also suggested an
approach to a range of ethical issues, such as the possibility of
accidental unblinding of genetic status to trial participants or the
revealing of disease status in pre-symptomatic studies of sporadic
disorders. The work is expected to inform the design of future
drug trials in pre-symptomatic disease, and particularly to lead to
the earlier consideration of ethical issues8.
DISCUSSION
The trans-national Working Groups mobilized under this
funding action brought together scientists from across the globe
to address methodological challenges that cannot, by definition,
be solved within the borders of any one country alone. The JPND
mechanism allowed groups to rapidly and efficiently provide
toolkits to assist scientists in their research planning, both to
unlock potential in existing studies and to help support new
research. Indeed there has already been some evidence of this,
with the funding of a proposal linked to the PreNI Working
Group under the JPND-European Commission co-funded call,
as well as the success of the METACOHORTSWorking Group in
securing Horizon 2020 funding9. The BRIDGET project, funded
in 2015 by JPND, will further expand the work done by HD-
READy10. More broadly, the connections made between group
members have in many cases continued beyond the funding
period, resulting in a rich stream of scientific publications.
In addition, there is evidence that the Working Groups
have stimulated new ideas. One example comes from the
group focused on harmonization and innovation of cognitive,
behavioral and functional assessment in dementia, which was
led by Alberto Costa of the IRCCS Fondazione Santa Lucia
and Niccolò Cusano University11. This group found that the
knowledge presently available on the validity, reliability and
accessibility of new tools for the evaluation of cognitive disorders
was limited. The goals identified by the Working Group were to
achieve a shared standard set of high sensitivity and specificity
tools for the pre-symptomatic stages of AD, the measurement
of change during longitudinal studies, and the assessment of
functional abilities.
Moreover, the systematic review of all data on the reliability
of image acquisition methods for vascular disease undertaken by
the METACOHORTS group provides essential underpinning for
future standardization work (De Guio et al., 2016). ThisWorking
Group also recognized that cerebral microvascular disease has
local and global effects on the brain, making the burden of
brain damage far greater than any individual focal neurological
symptom or visible lesion on a scan. As a consequence of this
observation, continuing efforts are being directed at assessing
variability of vascular risk vs. cerebrovascular disease burden
across different cohorts, examining patterns of accumulating
8http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-
Report-Rohrer.pdf
9http://cordis.europa.eu/project/rcn/199717_en.html
10http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/Fact-
Sheet_BRIDGET_v2.pdf
11http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/
JPND-Report-Costa.pdf
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brain damage and mechanisms, and improving clinical trial
methodologies.
The Working Groups continue to collaborate and share
information in various ways. Building on their previous work,
the PreNI group organized a successful international conference
on pre-symptomatic ND in London (convened by Lancet
Neurology, 19–21 October 2016). Several other groups are also
working on new projects that extend their work. One example
is BioLoC-PD, a Working Group led by Daniela Berg of the
Hertie-Institute for Clinical Brain Research that focused on the
harmonization of biomarker assessment in longitudinal cohort
studies in Parkinson’s disease (PD)12. After the group established
the enormous potential for future joint data analyses, members
of BioLoC-PD formed a partnership for data sharing, leading
to biomarker analyses with much larger and statistically robust
sample sizes, as well as to the replication of biomarker data in the
prodromal phase of PD (Lerche et al., 2015; Lawton et al., 2016).
Despite the progress made by the Working Groups, however,
several limitations were identified. For instance,Working Groups
reported that the short time frame of the project was a challenge.
For this reason, future actions should extend the time frame to
at least 9 months. One Working Group expressed concern that
obtaining funding for the reanalysis of existing data was more
challenging than for new data, suggesting that there could be
increased recognition by funders of the value of data mining and
reanalysis. Since the Working Groups were identified through an
open call, a concern was raised that such a mechanism might
be biased toward more established members of the community
including researchers who run large cohort studies and may
have determined the original conditions for access. The authors
acknowledge the importance of this point, but also maintain that
potential for conflict of interest could also exist in any other
group set up to examine these issues. Moreover, the policy of
most funders—including JPND—is now to require researchers
to make their data openly available for use by other groups. To
help ensure effectiveness, funders should require custodians to
operate transparent access mechanisms and have independent
representation on committees responsible for deciding cohort
access for research purposes. By facilitating a face-to-face
policy development meeting around these issues away from
the individual researchers’ own laboratories, the aim of JPND
was to kick-start progress toward, and lay the groundwork for,
the future provision of meaningful new community standards.
Finally, several Working Groups noted previous difficulty in
communicating their outputs and persuading the research
community to adopt the recommendedmeasures. This paper was
written partly to address this need.
CONCLUSIONS
Research solutions are urgently needed for ND, which are
associated with a huge social and economic burden, affecting
not only patients but those who care for them, and numbers
of patients worldwide are set to grow exponentially in coming
12http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/
JPND-Report-Berg.pdf
years. Cross-border, collaborative research will play a vital role in
generating future knowledge and understanding of human health
and disease, as well as in the development of safe and effective
treatments.
Sometimes in research, enabling steps are first required
before substantive studies can accelerate the pace of research
progress. In the case of the ND field it is well-recognized
that there is an urgent need to understand disease onset and
progression as a basis for future interventions, and in principle,
longitudinal cohort studies offer an excellent approach because
they provide a wealth of information available over time. Yet the
use of cohort studies in ND research has not been as prevalent
as expected, primarily due to very practical considerations
such as lack of knowledge about which cohorts are available
and suitable for what purposes, as well as more fundamental
methodological challenges, such as variations in data collection
and measurement.
The rapid, flexible funding mechanism leveraged in this
action represents a new cross-border funding tool that has
the potential to help accelerate scientific research rapidly and
at relatively low cost. This flexible funding approach is now
being extended to other JPND priority areas, with JPND again
implementing the mechanism in its 2016 call for Working
Groups for harmonization and alignment in brain imaging,
which draws on experience and expands the duration of the
award to 9 months.
The JPND Longitudinal Cohort Studies Working Groups
brought together some 200 leading experts to build consensus
around key challenges inhibiting research progress. The collective
outputs of the Working Groups demonstrate that the “rapid
action” approach described here has proved efficient and
effective, resulting in the stimulation of novel ideas, the formation
of new partnerships for future research or data sharing and the
development of best-practice frameworks that now form the
essential underpinnings for future standardization work.
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